Tobam Boosts Stock Position in Edwards Lifesciences Corporation $EW

Tobam raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,932 shares of the medical research company’s stock after purchasing an additional 1,195 shares during the period. Tobam’s holdings in Edwards Lifesciences were worth $3,514,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in Edwards Lifesciences in the first quarter worth approximately $26,000. SouthState Corp bought a new position in Edwards Lifesciences during the first quarter valued at approximately $27,000. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences during the 2nd quarter valued at approximately $28,000. Costello Asset Management INC bought a new stake in Edwards Lifesciences in the 1st quarter worth approximately $29,000. Finally, NewSquare Capital LLC increased its stake in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Sanford C. Bernstein reiterated a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Evercore ISI boosted their target price on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Stifel Nicolaus upped their price target on Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Robert W. Baird set a $83.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Trading Up 1.3%

EW stock opened at $85.14 on Wednesday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $87.09. The company’s 50-day simple moving average is $77.90 and its 200-day simple moving average is $77.53. The firm has a market cap of $49.41 billion, a P/E ratio of 12.25, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 22,970 shares of company stock worth $1,862,878 over the last quarter. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.